These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26590039)

  • 1. Editorial Comment.
    Shah P; Moreira DM
    Urology; 2015 Nov; 86(5):995-6. PubMed ID: 26590039
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial Comment.
    Klotz L
    Urology; 2015 Nov; 86(5):996. PubMed ID: 26590040
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment.
    Dall'Era M
    J Urol; 2013 Jul; 190(1):96. PubMed ID: 23624151
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply.
    Reese AC; Carter HB
    Urology; 2015 Nov; 86(5):997. PubMed ID: 26590041
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment.
    de Almeida JC
    Int Braz J Urol; 2014; 40(2):160. PubMed ID: 24987766
    [No Abstract]   [Full Text] [Related]  

  • 6. Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: Yes.
    van der Poel HG; van den Bergh RC
    Int Braz J Urol; 2016; 42(3):413-7. PubMed ID: 27286101
    [No Abstract]   [Full Text] [Related]  

  • 7. Early prostate cancer--treat or watch?
    Shigeta K; Naito Y; Takano T
    N Engl J Med; 2011 Aug; 365(6):568-9. PubMed ID: 21830973
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial Comment to Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Mearini L
    Int J Urol; 2015 Nov; 22(11):1035-6. PubMed ID: 26303376
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer: Time for active surveillance of intermediate-risk disease?
    Ahmed HU
    Nat Rev Urol; 2013 Jan; 10(1):6-8. PubMed ID: 23147924
    [No Abstract]   [Full Text] [Related]  

  • 10. Early prostate cancer--treat or watch?
    Klotz L; Thompson I
    N Engl J Med; 2011 Aug; 365(6):569. PubMed ID: 21830972
    [No Abstract]   [Full Text] [Related]  

  • 11. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
    Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
    J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Stenman UH
    Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment.
    Sundi D; Schaeffer EM
    Urology; 2014 Dec; 84(6):1261-2. PubMed ID: 25283701
    [No Abstract]   [Full Text] [Related]  

  • 14. Super active surveillance for low-risk prostate cancer | Opinion: No.
    Ghodoussipour S; Lebastchi AH; Bloom JB; Pinto PA; Berger A
    Int Braz J Urol; 2019; 45(2):215-219. PubMed ID: 31021585
    [No Abstract]   [Full Text] [Related]  

  • 15. Active surveillance and radical prostatectomy.
    Bangma CH
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S355-6. PubMed ID: 21944013
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment.
    Loeb S
    Urology; 2014 Aug; 84(2):371-2. PubMed ID: 24925831
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment.
    Carter HB
    Urology; 2009 Sep; 74(3):658; author reply 659. PubMed ID: 19716923
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment.
    Ho TS; Bañez LL; Freedland SJ
    Urology; 2011 Oct; 78(4):872-3. PubMed ID: 21982005
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prostatectomy vs. "watchful waiting" in early prostate cancer].
    Markun S
    Praxis (Bern 1994); 2014 Jul; 103(15):909-10. PubMed ID: 25051936
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
    Greene DR
    Eur Urol; 2007 Sep; 52(3):744-5. PubMed ID: 17350749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.